THERESA EVANS: Open Payments
NPI 1477012029 · COUNCIL BLUFFS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$849 in 44 payments from 24 companies in 2025. Trend: 2023 $372 · 2024 $1,298 · 2025 $849
Food & beverage: $849
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $135 |
| Celgene Corporation | 5 | $85 |
| ABBVIE INC. | 3 | $60 |
| Genentech USA, Inc. | 2 | $55 |
| GENZYME CORPORATION | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| EMD Serono, Inc. | 2 | $34 |
| PFIZER INC. | 2 | $34 |
| Stemline Therapeutics Inc. | 2 | $32 |
Products named: ALTUVIIIO, REBLOZYL, KISQALI, LUTATHERA, KEYTRUDA, ELAHERE, OPDIVO, RUBRACA.
Industry payments across IA — which companies pay providers there.
